Italy's €183M Pharma Antitrust Case Gets Boost From EU AG
Two drugs marketed to treat wildly different conditions may still be competitors under European Union antitrust law if doctors use one off-label for the other ailment, an adviser to the bloc's...To view the full article, register now.
Already a subscriber? Click here to view full article